Please provide your email address to receive an email when new articles are posted on . Patients had mild asthma and uncontrolled symptoms. Doses included an albuterol-budesonide combination or ...

Please provide your email address to receive an email when new articles are posted on . Risk and annualized rate of severe exacerbations dropped with as-needed use of albuterol-budesonide vs.

WILMINGTON, Del.--(BUSINESS WIRE)--Full results from the positive MANDALA Phase III trial showed that PT027 (albuterol/budesonide) at two different strengths of budesonide, an inhaled corticosteroid ...

asthma, lungs The combination therapy significantly reduced the risk of severe exacerbations and improved lung function. Topline results were announced from two phase 3 studies evaluating a fixed-dose ...

Credit: AstraZeneca. Airsupra combines albuterol, a short-acting beta2-agonist, and budesonide, an inhaled corticosteroid. Airsupra ® (albuterol/budesonide) is now available for the as-needed ...

As-needed albuterol-budesonide (Airsupra) more effectively improved lung function in moderate-to-severe asthma than as-needed albuterol only, according to research presented at the CHEST annual ...

Fixed-Dose Combination of Albuterol and Budesonide (PT027) Demonstrated Significant Benefits for Asthma Patients in MANDALA and DENALI Phase III Trials PT027 significantly reduced the risk of severe ...

Independent Data Monitoring Committee recommended trial stop early due to overwhelming efficacy at pre-planned analysis AstraZeneca’s inhaled anti-inflammatory rescue medication AIRSUPRA demonstrated ...

LOUISVILLE, Ky. -- An investigational fixed-dose combination of a short-acting beta 2-adrenergic agonist and an inhaled corticosteroid appeared to slow the deterioration in lung function and reduce ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AIRSUPRA’s US Prescribing Information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma. 1 The BATURA Phase IIIb trial, ...

A new medication approved for the treatment and prevention of bronchoconstriction and the reduction of exacerbation risks in asthmatics aged 18 and older. COLUMBUS ...